New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications for previously approved therapies – for people living with blood...

Online Exclusives

Opioid Overdose Tops List of Leading Causes of Death in the...

The odds of dying from an accidental opioid overdose in the U.S. are greater than those of dying in a car accident, according to...

U.S. Veterans to Have Increased Access to Private Care

As part of the Mission Act of 2018, the U.S. Department of Veterans Affairs (VA) is planning to allow veterans to use their health...

News

From the Blood Journals

WIB_icon

Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML

A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...
WIB_icon

Ravulizumab: A New Complement Inhibitor for Patients With Paroxysmal Nocturnal Hemoglobinuria

Ravulizumab was noninferior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had never received treatment with complement inhibitors, according to findings from...

Multimedia

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...

On Location

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after...

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab...

ECHELON-2: Brentuximab Vedotin Combination Outperforms CHOP for Peripheral T-Cell Lymphomas

Results from the phase III ECHELON-2 trial showed that brentuximab vedotin added to a combination...

Selinexor Induces Deep Responses in Refractory Multiple Myeloma

More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a...

REACHing Children With Sickle Cell Anemia in Sub-Saharan Africa

Daily treatment with hydroxyurea was feasible, well-tolerated, and safe for children with sickle cell anemia...

Latest Headlines

Advertisement

ASH Directions

ASH Recognizes Choosing Wisely Champions, Scholar Award Winners, and more

Recognizing Champions of Waste Reduction ASH recognized three Choosing Wisely® Champions during the 2018 annual meeting in San Diego. Choosing Wisely, an initiative of the American...

ASH Announces New Executive Committee Members, Hosts MDS+AML MATTER Education Program, and more

And The Winners Are … ASH has announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH...

Sign up for our
eNewsletter!

Remembering Peter R. Galbraith and Sir David Weatherall, FDA names Amy Abernethy new Deputy...

Remembering Peter R. Galbraith (1931 – 2018) Peter R. Galbraith, MD, FRCPC, an emeritus professor at Queen’s University in Kingston, Ontario, passed away on October...

Remembering Brian P. Sorrentino, NIH Awards Washington University Leukemia Program, and more

Remembering Brian P. Sorrentino (1958-2018) Brian P. Sorrentino, MD, a gene-therapy researcher specializing in the treatment of blood and immune cell disorders, passed away...

ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and more

American Society of Hematology Honors Distinguished Leaders at Annual Meeting At its 60th annual meeting, the American Society of Hematology (ASH) will present several distinguished...

New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...

Welcome to the Digital World

Over the past two decades, social media has become an integral part of everyday lives, with millions of people using it as an avenue...

Blood Beyond Borders: Malaria and Thalassemia in the Mediterranean Basin

In 1949, British scientist John Burdon Sanderson Haldane made a novel connection between red cell disorders and malaria: The genetic mutations that lead to...